RareStone Group

RareStone Group is dedicated to building the first rare disease ecosystem in the Greater China, to improve the lives of patients and families impacted by rare diseases, by bringing the best-in-the-world therapeutic solutions and comprehensive and sustainable service supports. RareStone Group consists of two business subsidiaries: Citrine Medicine and Zircon Health. Citrine Medicine is a pharmaceutical company and focused on providing effective and affordable therapeutic solutions to rare disease patients in the Greater China. Citrine Medicine currently focuses on 4 therapeutic areas: neurology, endocrinology, liver, kidney & metabolic diseases, and rare oncology. Citrine already has two assets WAKIX® & Alkindi® in pre-NDA stage for rare diseases in neurology and endocrinology, respectively. Zircon Health is a “service company” and aims to build the first ecosystem for rare disease in China, providing a patient-centered service platform for full disease management by leveraging AI, internet tools and big data analytics, and developing solutions to meet the unmet non-treatment needs of rare disease patients and families, as well as exploring innovative payment solutions to improve affordability. RareStone Group closed a USD80 million Series A financing in July 2020. Key investors include Eight Roads Ventures, F-Prime Capital, Vivo Capital. Our Vision: To become the leading company supporting the rare disease community in China. Our Mission: To provide individuals and families in China affected by rare diseases with access to the best, most effective medicines and treatment protocols available in the world. Our Approach: To build the first rare disease ecosystem in China to bring a support network and much needed treatments to individuals and their families affected by rare diseases.